A Retrospective Review of Sacubitril-Valsartan Combination Use in a Diverse Advanced Heart Failure Patient Population in a Community Hospital

Introduction: Sacubitril/valsartan combination (SVC) is a new member of the armamentarium for the treatment of heart failure (HF). In the PARADIGM-HF trial, when compared to enalapril, SVC showed a 21% reduction in the composite endpoint of death from cardiovascular causes or hospitalization for HF in mostly NYHA function class (FC) II to III HF with reduced ejection fraction (HFrEF). After its FDA approval in 2015, SVC received a Class I recommendation from the 2016 focused ACC/AHA/HFSA guidelines for patients with chronic HFrEF to reduce morbidity and mortality.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research